AboutKidsHealth

 

 

Drug treatment of congenital heart defects for premature babiesDDrug treatment of congenital heart defects for premature babiesDrug treatment of congenital heart defects for premature babiesEnglishNeonatology;CardiologyPremature;Newborn (0-28 days);Baby (1-12 months)HeartCardiovascular systemDrug treatmentPrenatal Adult (19+)NA2009-10-31T04:00:00ZPatrick McNamara, MB, BCh, BAO, FRCPC12.000000000000036.0000000000000630.000000000000Flat ContentHealth A-Z<p>Learn about drug treatments available for congenital heart defects, which depend on the part of the heart affected. Many heart defects are easily managed.</p><p>Treatment of congenital heart defects depends on which part of the heart is affected. In some cases, depending on the severity of the heart defect, drug treatment is the best option.</p><h2>Key points</h2> <ul><li>Treatment of congenital heart defects depends on which part of the heart is affected, a baby's size and weight, and the presence of other conditions or complications.</li> <li>Babies who are given drug therapy for a heart defect will be carefully monitored in the NICU.</li></ul>
Pharmacothérapie des cardiopathies congénitales aux bébés prématurésPPharmacothérapie des cardiopathies congénitales aux bébés prématurésDrug treatment of congenital heart defects for premature babiesFrenchNeonatology;CardiologyPremature;Newborn (0-28 days);Baby (1-12 months)HeartCardiovascular systemDrug treatmentPrenatal Adult (19+)NA2009-10-31T04:00:00ZPatrick McNamara, MB, BCh, BAO, FRCPC12.000000000000036.0000000000000630.000000000000Flat ContentHealth A-Z<p>Renseignez-vous au sujet des pharmacothérapies disponibles en ce qui concerne les cardiopathies congénitales, qui dépendent de la partie du cœur touchée.</p><p>Le traitement des malformation cardiaque congénitales dépend de la partie du cœur qui est touchée. Dans certains cas, selon la gravité de la cardiopathie congénital, le traitement médicamenteux est la meilleure option.</p><h2>À retenir</h2> <ul><li>Le traitement des malformation cardiaque congénitales dépend de la partie du cœur qui est touchée, de la taille et du poids du bébé ainsi que de la présence d’autres troubles ou complications.</li> <li>Les bébés qui reçoivent une pharmacothérapie pour une malformation cardiaque seront étroitement surveillés à l’unité néonatale des soins intensifs. </li></ul>

 

 

Drug treatment of congenital heart defects for premature babies1840.00000000000Drug treatment of congenital heart defects for premature babiesDrug treatment of congenital heart defects for premature babiesDEnglishNeonatology;CardiologyPremature;Newborn (0-28 days);Baby (1-12 months)HeartCardiovascular systemDrug treatmentPrenatal Adult (19+)NA2009-10-31T04:00:00ZPatrick McNamara, MB, BCh, BAO, FRCPC12.000000000000036.0000000000000630.000000000000Flat ContentHealth A-Z<p>Learn about drug treatments available for congenital heart defects, which depend on the part of the heart affected. Many heart defects are easily managed.</p><p>Treatment of congenital heart defects depends on which part of the heart is affected. In some cases, depending on the severity of the heart defect, drug treatment is the best option.</p><h2>Key points</h2> <ul><li>Treatment of congenital heart defects depends on which part of the heart is affected, a baby's size and weight, and the presence of other conditions or complications.</li> <li>Babies who are given drug therapy for a heart defect will be carefully monitored in the NICU.</li></ul><p> Some infants will not need treatment if the effect on blood flow is minor, while others will require medication or intervention such as cardiac catheterization or surgery. Many heart defects can be successfully managed, often in early infancy and sometimes even in the womb, before the baby is born. Some defects aren’t treated right away, but are treated when the child is older. And some defects are treated in stages. While heart defects generally aren't “cureable,” they can be managed well enough to enable the child to function well. </p><p>Treatment of congenital heart malformations must also take into consideration other factors and complications that are frequently present in premature babies. A baby’s size and weight may be considered too small for surgery and so surgical procedures to repair heart malformations may have to wait until the baby has grown and is in a better position to endure the surgery. </p><p>If other complications are present, such as lung problems, these issues may also change the course, timing, and perhaps outcome of treatment. </p><h2>Drug therapy</h2><p>Depending on the type of heart defect an infant has, it may be beneficial to have the ductus arteriosus remain open. In the womb, the fetus gets oxygen from the mother. As there is no need for blood to pass through the lungs of the fetus, the blood is diverted away from the lungs by an artery called the ductus arteriosus. </p><p>Under normal conditions, once a baby is born, the ductus arteriosus begins to close, never to open again. However, with certain types of congenital heart defects, having some of the blood continue to be diverted away from the lungs is a benefit for a period of time. To keep a ductus arteriosus open, a baby will be given prostaglandin E2 (PgE2) which encourages the ductus arteriosus to remain patent or open. In some cases, this treatment will continue for weeks or months until such time as the baby is deemed ready enough for surgery. Special care will be given to the amount of PgE2 administered to the baby since there are several complications that can arise from its use such as apnea or periodic interruptions in breathing, gastric outlet obstruction which is a condition that makes emptying the bowels difficult, and hyperostosis or abnormal bone growth. </p><h2>Monitoring</h2><p>All babies in the NICU are monitored. Those with congenital heart malformations will be monitored specifically to confirm that blood flow and circulation in general, though probably abnormal at least to some extent, remains strong enough to sustain the baby until such time as surgery or some other treatment can begin. In other words, the abnormal blood flow should still be able to deliver sufficient oxygen to all parts of the body so that the baby can gain strength and does not worsen while waiting for the next step in treatment. </p><p>Levels of plasma lactate and signs of metabolic acidosis will be checked to monitor the adequacy of the blood flow. If the baby is receiving PgE2, or other medications, monitoring ensures that the medications are having the desired effect and that side effects do not adversely effect the baby.</p><p>More information:<br></p><ul><li> <a href="/Article?contentid=1767&language=English">Congenital heart defects in premature babies</a></li><li> <a href="/Article?contentid=1604&language=English">Diagnosis of congenital heart defects in premature babies</a></li><li> <a href="/Article?contentid=1841&language=English">Surgical treatment of congenital heart defects for premature babies</a></li></ul>Drug treatment of congenital heart defects for premature babies

Thank you to our sponsors

AboutKidsHealth is proud to partner with the following sponsors as they support our mission to improve the health and wellbeing of children in Canada and around the world by making accessible health care information available via the internet.